Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
By K. Schultz, W. Bowman, A. Aledo, W. Slayton, H. Sather, M. Devidas, Chenguang Wang, S. Davies, P. Gaynon, M. Trigg and 10 more. Journal of Clinical Oncology, 2009
688 citations recorded by the source corpus.
Subfields: Hematology, Oncology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/931c52c31a64d8bde53d2b5b479882b12d3d8459
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “Clinical targeting of BCR-ABL gene, formed by the fusion of ABL gene from chromosome 9 to the BCR gene on chromosome 22, also called the Philadelphia chromosome, improved the clinical management of leukemia patients [76, 77].”
- Biology, risk stratification, and therapy of pediatric acute leukemias: an update. (2011, result): “In a recent COG study, the addition of continuous exposure of imatinib into an intensive chemotherapy regimen has yielded a 3-year event-free survival of 80%, more than twice that of the historical controls.(37) Patients who were treated with intensive chemotherapy plus imatinib fared as least as we”
- Acute Lymphoblastic Leukemia in Children (2013, background): “In a recent COG study, intensive chemotherapy plus continuos imatinib exposure after remission induction therapy yielded a 3-year EFS of 80%, more than twice that of historical controls, and comparable to those of matched-related or matched-unrelated transplant [135].”
- Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia (2012, background): “The dramatic improvement in outcome observed in Ph B-ALL patients treated with chemotherapy and imatinib (Schultz et al., 2009) and our demonstration that Ph-like leukemic cells are sensitive to currently available TKIs provide a strong rationale to test chemotherapy plus TKI treatment in Ph-like AL”
- Outcomes for children and adolescents with cancer: challenges for the twenty-first century. (2010, background): “Proof of concept for the dramatic impact of effective targeted agents in the pediatric setting is seen for both all-trans retinoic acid for acute promyelocytic leukemia14 and for imatinib for Philadelphia chromosome–positive ALL.57,58 In each case, the targeted agent blocked the activity of a cancer”